Historically, ALK = negative ALCL exhibited the worse prognosis of any subtype in the group; however, the introduction of Brentuximab vedotin into CHOP (Bv-CHP) has now shown that even this entity does equally as well as ALK-positive ALCL [37]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.